Susquehanna International Group, LLP Aurinia Pharmaceuticals Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

29 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$5.32 - $7.33 $1.67 Million - $2.3 Million	313,100 Added 206.67%	464,600 $3.41 Million
Q2 2024 Aug 15, 2024	SELL	$4.81 - $5.78 $768,637 - $923,644	-159,800 Reduced 51.33%	151,500 $865,000
Q1 2024 May 07, 2024	BUY	$4.93 - $9.31 $964,308 - $1.82 Million	195,600 Added 169.06%	311,300 $1.56 Million
Q4 2023 Feb 14, 2024	SELL	$7.13 - $9.49 $771,466 - $1.03 Million	-108,200 Reduced 48.33%	115,700 $1.04 Million
Q3 2023 Nov 14, 2023	BUY	$7.77 - $12.27 $254,079 - $401,229	32,700 Added 17.1%	223,900 $1.74 Million
Q2 2023 Aug 11, 2023	SELL	$8.96 - $11.69 $52,864 - $68,971	-5,900 Reduced 2.99%	191,200 $1.85 Million
Q1 2023 May 16, 2023	SELL	$5.94 - $11.27 $554,202 - $1.05 Million	-93,300 Reduced 32.13%	197,100 $2.16 Million
Q4 2022 Feb 14, 2023	SELL	$4.11 - $8.14 $1.26 Million - $2.49 Million	-306,200 Reduced 51.32%	290,400 $1.25 Million
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $539,460 - $1 Million	81,000 Added 15.71%	596,600 $4.49 Million
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $6.39 Million - $9.14 Million	-714,000 Reduced 58.07%	515,600 $5.18 Million
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $3.96 Million - $8.86 Million	-394,200 Reduced 24.28%	1,229,600 $15.2 Million
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $14.4 Million - $26.7 Million	807,700 Added 98.97%	1,623,800 $37.1 Million
Q3 2021 Nov 15, 2021	SELL	$10.93 - $23.55 $108,207 - $233,145	-9,900 Reduced 1.2%	816,100 $18.1 Million
Q2 2021 Aug 11, 2021	BUY	$10.0 - $14.52 $4.5 Million - $6.53 Million	449,900 Added 119.62%	826,000 $10.7 Million
Q1 2021 May 17, 2021	BUY	$12.3 - $18.73 $2.79 Million - $4.25 Million	226,700 Added 151.74%	376,100 $4.88 Million
Q4 2020 Feb 16, 2021	SELL	$12.94 - $16.05 $2.14 Million - $2.65 Million	-165,300 Reduced 52.53%	149,400 $2.07 Million
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $236,101 - $298,214	17,900 Added 6.03%	314,700 $4.64 Million
Q2 2020 Aug 14, 2020	SELL	$14.12 - $18.33 $1 Million - $1.3 Million	-70,900 Reduced 19.28%	296,800 $4.82 Million
Q1 2020 May 15, 2020	SELL	$11.34 - $21.46 $809,676 - $1.53 Million	-71,400 Reduced 16.26%	367,700 $5.34 Million
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $20,952 - $115,668	5,400 Added 1.25%	439,100 $8.9 Million
Q3 2019 Nov 14, 2019	BUY	$5.34 - $6.59 $906,198 - $1.12 Million	169,700 Added 64.28%	433,700 $2.32 Million
Q2 2019 Aug 14, 2019	BUY	$6.05 - $6.75 $1.43 Million - $1.59 Million	235,700 Added 832.86%	264,000 $1.74 Million
Q1 2019 May 15, 2019	SELL	$6.06 - $7.64 $192,708 - $242,952	-31,800 Reduced 52.91%	28,300 $184,000
Q4 2018 Feb 14, 2019	SELL	$5.08 - $6.83 $769,112 - $1.03 Million	-151,400 Reduced 71.58%	60,100 $410,000
Q3 2018 Nov 14, 2018	BUY	$5.27 - $6.64 $878,508 - $1.11 Million	166,700 Added 372.1%	211,500 $1.4 Million
Q2 2018 Aug 14, 2018	BUY	$5.06 - $6.36 $16,698 - $20,988	3,300 Added 7.95%	44,800 $252,000
Q1 2018 May 15, 2018	SELL	$4.85 - $5.99 $21,825 - $26,955	-4,500 Reduced 9.78%	41,500 $215,000
Q4 2017 Feb 14, 2018	SELL	$4.53 - $7.09 $418,572 - $655,116	-92,400 Reduced 66.76%	46,000 $208,000
Q3 2017 Nov 14, 2017	BUY	$5.71 - $6.9 $790,264 - $954,960	138,400	138,400 $868,000

Others Institutions Holding AUPH

# of Institutions

209

Shares Held

58.7M

Call Options Held

1.14M

Put Options Held

1.51M

Black Rock Inc. New York, NY

9.27M
Shares

$75.3 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

8.2M
Shares

$66.6 Million
1.0% of portfolio
Tang Capital Management LLC San Diego, CA

7.23M
Shares

$58.7 Million
4.52% of portfolio
Nea Management Company, LLC Timonium, MD

3.97M
Shares

$32.2 Million
2.22% of portfolio
State Street Corp Boston, MA

2.95M
Shares

$23.9 Million
0.0% of portfolio

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account